AGENDA |
| Monday, October 13, 2008 |
Registration and Continental Breakfast
Welcome and Introduction
Dr. Leroy Nyberg, NIDDK, NIH
Comments from the Director
Dr. Robert Star, DKUHD, NIDDK, NIH
Why Study Modifiable Risk Factors for BPH and LUTS?
Dr. Elizabeth Platz, Johns Hopkins Bloomberg School of Public Health
What Do We Know about the Epidemiology of BPH and LUTS?
Dr. Steven Jacobsen, Southern California Permanente Medical Group
What Has Basic Science Informed Us about the Etiology of BPH and LUTS?
Dr. Kevin McVary, Northwestern University Medical School
Break |
| |
| Theme I: Endpoint Definition and Measurement |
Currently Used Definitions and Clinical Methods to Diagnose BPH/LUTS
Dr. John Wei, University of Michigan School of Medicine
Currently Used Definitions of BPH/LUTS in Epidemiologic Studies
Dr. Aruna Sarma, University of Michigan Health System
Defining New Phenotypes for BPH/LUTS for Use in Epidemiologic Studies br> Dr. Elizabeth Platz, Johns Hopkins Bloomberg School of Public Health
Dr. Steven Jacobsen, Southern California Permanente Medical Group
Developing a Consensus Statement for Defining and Measuring BPH/LUTS in Epidemiologic Studies:
Report from June 2 Roundtable
Dr. Elizabeth Platz, Johns Hopkins Bloomberg School of Public Health
Lunch (on your own) |
| |
| Theme II: Modifiable Risk Factors |
Energy Imbalance, Obesity, Inactivity, and Energy Intake
Dr. Edward Giovannucci, Harvard School of Public Health
Sequelae of Energy Imbalance: Insulin
Dr. Sabine Rohrmann, German Cancer Research Center
Sequelae of Energy Imbalance: Autonomic Nervous System Activity
Dr. Jennifer St. Sauver, Mayo Clinic
Break
Tobacco and Alcohol Use
Dr. Cynthia Girman, Merck Research Laboratories
Diet and Nutrients
Dr. Alan Kristal, Fred Hutchinson Cancer Research Center
Drugs, Including Statins and Anti-Inflammatories
Dr. Susan Hall, New England Research Institutes |
| |
| Theme III: Epidemiologic Studies on LUTS/BPH |
Cohort Studies Not Originally Designed to Study LUTS/BPH
Dr. Stephen Van Den Eeden, Kaiser Permanente
Cohort Studies Designed to Study LUTS/BPH
Dr. Varant Kupelian, New England Research Institutes
Designing Future Observational Studies: Issues and Opportunities
Dr. Alan Kristal, Fred Hutchinson Cancer Research Center |
| |
| Tuesday, October 14, 2008 |
| Registration and Continental Breakfast |
| |
| Theme IV: Novel Approaches to Understanding How Modifiable Risk Factors Influence BPH/LUTS |
Tissue Biomarkers and Pre-Clinical Models
Dr. Beatrice Knudsen, Fred Hutchinson Cancer Research Center
Incorporating Measures of Inflammation and Its Modifiable Causes Including Infection into Epidemiologic
Studies of BPH/LUTS
Dr. J. Kellogg Parsons, University of California at San Diego
Designing Clinical Trials of BPH/LUTS Prevention Focused on Modifiable Risk Factors
Dr. Michael Barry, Massachusetts General Hospital
Break |
| Concurrent Breakout Sessions |
| Breakout Session 1: | Theme I: Endpoint Definition and Measurement
Session Co-leaders:
Dr. John Wei, University of Michigan School of Medicine
Dr. Edward Giovannucci, Harvard School of Public Health |
| Breakout Session 2: | Theme II: Modifiable Risk Factors
Session Co-leaders:
Dr. J. Kellogg Parsons, University of California at San Diego
Dr. Alan Kristal, Fred Hutchinson Cancer Research Center |
| Breakout Session 3: | Theme III: Epidemiologic Studies on LUTS/BPH
Session Co-leaders:
Dr. Cynthia Girman, Merck Research Laboratories
Dr. David Penson, University of Southern California/Norris Comprehensive Cancer Center |
| Breakout Session 4: | Theme IV: Novel Approaches to Understanding How Modifiable Risk Factors Influence BPH/LUTS
Session Co-leaders:
Dr. Elizabeth Platz, Johns Hopkins Bloomberg School of Public Health
Dr. Steven Jacobsen, Southern California Permanente Medical Group |
| Report on Findings from Breakout Sessions |
Summary and End of Workshop
Dr. Elizabeth Platz, Johns Hopkins Bloomberg School of Public Health |